IDXG Stock - Interpace Biosciences, Inc.
Unlock GoAI Insights for IDXG
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $46.93M | $40.21M | $31.84M | $41.31M | $32.40M |
| Gross Profit | $29.93M | $23.90M | $18.23M | $17.95M | $10.72M |
| Gross Margin | 63.8% | 59.4% | 57.3% | 43.4% | 33.1% |
| Operating Income | $8.11M | $2.80M | $-3,840,000 | $-11,737,000 | $-26,555,000 |
| Net Income | $6.70M | $802,000 | $-5,865,000 | $-14,746,000 | $-26,201,000 |
| Net Margin | 14.3% | 2.0% | -18.4% | -35.7% | -80.9% |
| EPS | $1.42 | $0.19 | $-1.38 | $-3.57 | $-6.50 |
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Visit WebsiteEarnings History & Surprises
IDXGEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q4 2025 | Nov 12, 2025 | — | $0.04 | — | — |
Q3 2025 | Aug 8, 2025 | — | $-0.12 | — | — |
Q2 2025 | May 8, 2025 | — | $0.06 | — | — |
Q1 2025 | Mar 31, 2025 | — | $0.66 | — | — |
Q4 2024 | Nov 4, 2024 | — | $0.31 | — | — |
Q3 2024 | Aug 2, 2024 | — | $0.48 | — | — |
Q2 2024 | May 9, 2024 | — | $0.13 | — | — |
Q2 2024 | Apr 1, 2024 | $-0.25 | $-3.35 | -1240.0% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $-0.01 | $-0.12 | -1100.0% | ✗ MISS |
Q3 2023 | Aug 9, 2023 | $-0.08 | $0.09 | +212.5% | ✓ BEAT |
Q2 2023 | May 12, 2023 | $-0.19 | $0.10 | +152.6% | ✓ BEAT |
Q1 2023 | Mar 27, 2023 | $-0.07 | $-0.33 | -371.4% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.25 | $-0.30 | -20.0% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $-0.52 | $-0.92 | -76.9% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-0.80 | $-0.52 | +35.0% | ✓ BEAT |
Q1 2022 | Mar 31, 2022 | $-0.32 | $-0.90 | -181.3% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.62 | $-0.85 | -37.1% | ✗ MISS |
Q3 2021 | Aug 10, 2021 | $-1.01 | $-0.90 | +10.9% | ✓ BEAT |
Q2 2021 | May 11, 2021 | $-1.43 | $-1.02 | +28.7% | ✓ BEAT |
Latest News
Frequently Asked Questions about IDXG
What is IDXG's current stock price?
What is the analyst price target for IDXG?
What sector is Interpace Biosciences, Inc. in?
What is IDXG's market cap?
Does IDXG pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to IDXG for comparison